Dopamine
|
Basic information |
| Metabolite name | Dopamine |
 | HMDB0000073 |
 |
C03758 |
 |
681 |
| Synonyms | NA |
| No. of studies | 54 |
|
Basic information |
| Metabolite name | Dopamine |
| HMDB0000073 |
|
C03758 |
|
681 |
| Synonyms | NA |
| No. of studies | 54 |
|
Relationship between Dopamine and depression (count: 54) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type2 | CUMS + QZ group vs. CUMS group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M079 | Type1 | prolonged LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M079 | Type1 | acute LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Up |
| Study M098 | Type1 | depressed group vs. control group | Peripheral blood mononuclear cell | Human | Down |
| Study M1004 | Type2 | CUMS + Zhi-Zi-Chi decoctions group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1054 | Type1 | CUMS group vs. control group | Plasma | ICR mouse | Down |
| Study M1054 | Type2 | CUMS + ChaihuYujinxiang granules group vs. CUMS group | Plasma | ICR mouse | Up |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1095 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Down |
| Study M1095 | Type2 | CUMS + matrine group vs. CUMS group | Faece | ICR mouse | Up |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1106 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1106 | Type2 | CUMS + high dose of Compound Gaoziban tablet group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1106 | Type2 | CUMS + middle dose of Compound Gaoziban tablet group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1136 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1136 | Type2 | CUMS + middle dose of punicalagin group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1136 | Type2 | CUMS + high dose of punicalagin group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1136 | Type2 | CUMS + low dose of punicalagin group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1138 | Type1 | unpredictable subchronic stress group vs. control group | Hippocampus | Swiss mouse | Down |
| Study M168 | Type1 | OBX group vs. control group | Cerebrospinal fluid | Wistar rat | Down |
| Study M176 | Type1 | CUMS group vs. control group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M176 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + low dose of HCPE group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + low dose of HCPE group vs. CUMS group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + high dose of HCPE group vs. CUMS group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + middle dose of HCPE group vs. CUMS group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M176 | Type2 | CUMS + paroxetine group vs. CUMS group | Frontal cortex | Sprague-Dawley rat | Up |
| Study M179 | Type1 | CUMS group vs. control group | Cerebral cortex | BALB/c mouse | Down |
| Study M179 | Type1 | CUMS group vs. control group | Hippocampus | BALB/c mouse | Down |
| Study M179 | Type2 | CUMS + paroxetine group vs. CUMS group | Cerebral cortex | BALB/c mouse | Up |
| Study M179 | Type2 | CUMS + high dose of DNL group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M179 | Type2 | CUMS + middle dose of DNL group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M179 | Type2 | CUMS + low dose of DNL group vs. CUMS group | Cerebral cortex | BALB/c mouse | Up |
| Study M179 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M179 | Type2 | CUMS + high dose of DNL group vs. CUMS group | Cerebral cortex | BALB/c mouse | Up |
| Study M483 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M522 | Type2 | CUMS + NaP group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M523 | Type1 | CUMS group vs. control group | Brain | Wistar rat | Down |
| Study M525 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M558 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M558 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + low dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + high dose of SGHWT group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M558 | Type2 | CUMS + high dose of terpenoids group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M574 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M574 | Type1 | CMS + n-3 PUFA deficiency group vs. control + n-3 PUFA deficiency group | Hippocampus | Sprague-Dawley rat | Down |
| Study M581 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M581 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M634 | Type1 | CUMS group vs. control group | Cerebrospinal fluid | C57BL/6 mouse | Down |
| Study M634 | Type2 | CUMS + escitalopram group vs. CUMS group | Cerebrospinal fluid | C57BL/6 mouse | Up |
| Study M634 | Type2 | CUMS + PUFA group vs. CUMS group | Cerebrospinal fluid | C57BL/6 mouse | Up |
| Study M650 | Type3 | middle dose of decursin group vs. hispidol control group, after TST | Brain | ICR mouse | Up |
| Study M650 | Type3 | high dose of decursin group vs. hispidol control group, after TST | Brain | ICR mouse | Up |
| Study M689 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M689 | Type2 | CUMS + Danzhi Xiaoyao Powder group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M698 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M698 | Type2 | CUMS + Saikosaponin A group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M711 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M713 | Type1 | CUMS group vs. control group, week 3 | Hippocampus | C57BL/6 mouse | Up |
| Study M713 | Type1 | CUMS group vs. control group, week 5 | Hippocampus | C57BL/6 mouse | Down |
| Study M714 | Type1 | corticosterone group vs. control group, week 3 | Hippocampus | C57BL/6 mouse | Down |
| Study M714 | Type1 | corticosterone group vs. control group, week 5 | Hippocampus | C57BL/6 mouse | Down |
| Study M720 | Type1 | CUMS susceptible group vs. control group | Habenula | Sprague-Dawley rat | Down |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M732 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M732 | Type2 | CUMS + low dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M758 | Type1 | CUMS group vs. control group | Ventral tegmental area | Sprague-Dawley rat | Down |
| Study M758 | Type1 | CUMS group vs. control group | Nucleus accumbens | Sprague-Dawley rat | Down |
| Study M758 | Type2 | CUMS + high dose of Shuganheweitang group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of volatile oil group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + fluoxetine group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of volatile oil group vs. CUMS group | Ventral tegmental area | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of terpenoid group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + low dose of Shuganheweitang group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of terpenoid group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M758 | Type2 | CUMS + high dose of Shuganheweitang group vs. CUMS group | Nucleus accumbens | Sprague-Dawley rat | Up |
| Study M760 | Type1 | CUMS group vs. control group | Hippocampus | Rat | Down |
| Study M764 | Type1 | pentylenetetrazol group vs. control group | Cortex | Swiss albino mouse | Down |
| Study M764 | Type1 | pentylenetetrazol group vs. control group | Hippocampus | Swiss albino mouse | Down |
| Study M764 | Type2 | pentylenetetrazol + high dose of embelin group vs. pentylenetetrazol group | Cortex | Swiss albino mouse | Up |
| Study M764 | Type2 | pentylenetetrazol + high dose of embelin group vs. pentylenetetrazol group | Hippocampus | Swiss albino mouse | Up |
| Study M767 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M767 | Type1 | CUMS group vs. control group | Amygdala | C57BL/6 mouse | Down |
| Study M767 | Type1 | CUMS group vs. control group | Cortex | C57BL/6 mouse | Down |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Amygdala | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Striatum | C57BL/6 mouse | Up |
| Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Up |
| Study M822 | Type1 | CUS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M822 | Type1 | CUS group vs. control group | Cortex | Sprague-Dawley rat | Down |
| Study M832 | Type3 | dehydrozingerone 3h group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M832 | Type3 | dehydrozingerone 1h group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M832 | Type3 | escitalopram group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M848 | Type1 | CRS group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M848 | Type2 | CRS + dexamethasone group vs. CRS group | Serum | C57BL/6 J mouse | Up |
| Study M851 | Type1 | corticosterone group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M851 | Type2 | corticosterone + fluoxetine group vs. corticosterone group | Hippocampus | Sprague-Dawley rat | Up |
| Study M851 | Type2 | corticosterone + high dose of Zhi-Zi-Hou-Po Decoction group vs. corticosterone group | Hippocampus | Sprague-Dawley rat | Up |
| Study M889 | Type1 | CUMS group vs. control group | Hippocampus | BALB/c mouse | Down |
| Study M889 | Type1 | CUMS group vs. control group | Serum | BALB/c mouse | Down |
| Study M889 | Type2 | CUMS + high dose of Jiaotai Pills group vs. CUMS group | Serum | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + low dose of Jiaotai Pills group vs. CUMS group | Serum | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + low dose of Jiaotai Pills group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | BALB/c mouse | Up |
| Study M889 | Type2 | CUMS + high dose of Jiaotai Pills group vs. CUMS group | Hippocampus | BALB/c mouse | Up |
| Study M922 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M922 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M922 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + high dose of P. orientalis group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M922 | Type2 | CUMS + high dose of P. orientalis group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M927 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M927 | Type2 | CUMS + Zhi-zi-chi decoction group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M942 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Amygdala | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M942 | Type1 | CUMS group vs. control group | Striatum | C57BL/6 mouse | Down |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M942 | Type2 | CUMS + berberine group vs. CUMS group | Amygdala | C57BL/6 mouse | Up |
| Study M971 | Type2 | CUMS + Tao-Hong-Si-Wu decoction group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M978 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M985 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M985 | Type2 | CUMS + indole acetic acid group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |
| Study M994 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M994 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M994 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M994 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M994 | Type2 | CUMS + Uncaria rhynchophylla extract group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M994 | Type2 | CUMS + Uncaria rhynchophylla extract group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |